PofoliaShared via Pofolia

Diabetes Technology & Therapeutics· 2026Q1

Continuous Glucose Monitoring Is Not Ready for the Diagnosis of Prediabetes

J. Hans DeVries

Short summary

Continuous Glucose Monitoring (CGM) cannot reliably diagnose prediabetes, with the best discriminator (88% specificity, 48% sensitivity) failing to provide sufficient accuracy.

AI-generated from the title and abstract; the full text is not read.

Key points

  • CGM shows large overlap in glucose profiles between prediabetes and normoglycemia.
  • The best CGM discriminator (Time above 140 mg/dL at 5.64%) had 88% specificity but only 48% sensitivity.
  • CGM showed poor agreement with venous sampling for categorizing normoglycemia, prediabetes, and diabetes.
  • HbA1c is currently the most practical method for diagnosing prediabetes.

AI-generated from the title and abstract; the full text is not read.

Abstract

With the growing availability of over-the-counter continuous glucose monitors, the question arises whether Continuous Glucose Monitoring (CGM) can be used to diagnose prediabetes. Traditionally, prediabetes is diagnosed using the oral Glucose Tolerance Test, a test with poor reproducibility. In a study from Singapore, there was large overlap between Ambulatory Glucose Profiles of people with prediabetes and normoglycemia. The optimal threshold of 5.64% Time above 140 mg/dL, the best discriminator, yielded 88% specificity and 48% sensitivity, indicating insufficient discriminatory value in many cases. In a study from Stanford, administration of a 75-gram oral glucose load while wearing CGM showed poor agreement with venous sampling between the category outcomes normoglycemia, prediabetes and diabetes. Future large cohort studies and AI may improve this situation. But for the moment, when a question of prediabetes arises, the most practical answer is to measure HbA1c, which allows for an elegant classification of normoglycemia, prediabetes and diabetes.

The authors' abstract, as published at the source. Diabetes Technology & Therapeutics, 2026 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Endocrinology, Diabetes and Metabolism

Endocrinology, Diabetes and MetabolismMedicine